Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225

Benzinga Newsdesk www.benzinga.com Neutral 47.3%

Neg 0% Neu 47.3% Pos 0%

Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $227 to $225.